BRAF 変異を有する転移性または切除不能な結腸直腸癌患者に対する標準治療へのニボルマブの追加の試験
治療歴あり、マイクロサテライト安定、BRAFV600E 転移性および/または切除不能な結腸直腸癌の患者を対象とした、ニボルマブを併用または併用しないエンコラフェニブおよびセツキシマブの無作為化第 II 相試験 (NSC #748726)
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVE:
I. To compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients with microsatellite stable (MSS), BRAF^V600E metastatic and/or unresectable colorectal cancer (CRC) randomized to treatment with nivolumab + encorafenib + cetuximab compared to encorafenib + cetuximab.
SECONDARY OBJECTIVES:
I. To compare overall response rate (ORR), including confirmed and unconfirmed, complete and partial response, according to RECIST 1.1 criteria between the two arms.
II. To compare overall survival (OS) between the two arms. III. To compare duration of response between the two arms. IV. To compare safety and tolerability between the two arms. V. To assess immune-related PFS using modified response criteria adapted for immunotherapy (irRC-PFS) in patients treated with nivolumab + encorafenib + cetuximab.
BANKING OBJECTIVE:
I. To bank tissue and blood specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive encorafenib orally (PO) once daily (QD) on days 1-28, cetuximab intravenously (IV) on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed until death or 3 years after registration, whichever occurs first.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Goodyear、Arizona、アメリカ、85338
- CTCA at Western Regional Medical Center
-
-
California
-
Carmichael、California、アメリカ、95608
- Mercy San Juan Medical Center
-
Carmichael、California、アメリカ、95608
- Mercy Cancer Center - Carmichael
-
Dublin、California、アメリカ、94568
- Kaiser Permanente Dublin
-
Elk Grove、California、アメリカ、95758
- Mercy Cancer Center - Elk Grove
-
Fremont、California、アメリカ、94538
- Kaiser Permanente-Fremont
-
Fresno、California、アメリカ、93720
- Kaiser Permanente-Fresno
-
Irvine、California、アメリカ、92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Modesto、California、アメリカ、95356
- Kaiser Permanente-Modesto
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Rocklin、California、アメリカ、95765
- Mercy Cancer Center - Rocklin
-
Roseville、California、アメリカ、95661
- Kaiser Permanente-Roseville
-
Sacramento、California、アメリカ、95814
- Kaiser Permanente Downtown Commons
-
Sacramento、California、アメリカ、95823
- Kaiser Permanente-South Sacramento
-
Sacramento、California、アメリカ、95816
- Mercy Cancer Center - Sacramento
-
San Francisco、California、アメリカ、94115
- Kaiser Permanente-San Francisco
-
San Jose、California、アメリカ、95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro、California、アメリカ、94577
- Kaiser Permanente San Leandro
-
Santa Clara、California、アメリカ、95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa、California、アメリカ、95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco、California、アメリカ、94080
- Kaiser Permanente-South San Francisco
-
Vallejo、California、アメリカ、94589
- Kaiser Permanente-Vallejo
-
Walnut Creek、California、アメリカ、94596
- Kaiser Permanente-Walnut Creek
-
Woodland、California、アメリカ、95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
Colorado Springs、Colorado、アメリカ、80909
- UCHealth Memorial Hospital Central
-
Colorado Springs、Colorado、アメリカ、80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs、Colorado、アメリカ、80920
- Memorial Hospital North
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- Cancer Care and Hematology-Fort Collins
-
Greeley、Colorado、アメリカ、80631
- UCHealth Greeley Hospital
-
Highlands Ranch、Colorado、アメリカ、80129
- UCHealth Highlands Ranch Hospital
-
Loveland、Colorado、アメリカ、80538
- Medical Center of the Rockies
-
-
Georgia
-
Newnan、Georgia、アメリカ、30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、アメリカ、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、アメリカ、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Barrington、Illinois、アメリカ、60010
- Advocate Good Shepherd Hospital
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake、Illinois、アメリカ、60014
- AMG Crystal Lake - Oncology
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、アメリカ、61021
- Illinois CancerCare-Dixon
-
Downers Grove、Illinois、アメリカ、60515
- Advocate Good Samaritan Hospital
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Elgin、Illinois、アメリカ、60123
- Advocate Sherman Hospital
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Hazel Crest、Illinois、アメリカ、60429
- Advocate South Suburban Hospital
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville、Illinois、アメリカ、60048
- Condell Memorial Hospital
-
Libertyville、Illinois、アメリカ、60048
- AMG Libertyville - Oncology
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Oak Lawn、Illinois、アメリカ、60453-2699
- Advocate Christ Medical Center
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge、Illinois、アメリカ、60068
- Advocate Lutheran General Hospital
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Washington、Illinois、アメリカ、61571
- Illinois CancerCare - Washington
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- Northwest Cancer Center - Crown Point
-
Dyer、Indiana、アメリカ、46311
- Northwest Oncology LLC
-
Hobart、Indiana、アメリカ、46342
- Northwest Cancer Center - Hobart
-
Hobart、Indiana、アメリカ、46342
- Saint Mary Medical Center
-
Indianapolis、Indiana、アメリカ、46237
- Franciscan Health Indianapolis
-
Indianapolis、Indiana、アメリカ、46312
- Saint Catherine Hospital
-
Lafayette、Indiana、アメリカ、47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City、Indiana、アメリカ、46360
- Woodland Cancer Care Center
-
Mooresville、Indiana、アメリカ、46158
- Franciscan Health Mooresville
-
Munster、Indiana、アメリカ、46321
- The Community Hospital
-
Munster、Indiana、アメリカ、46321
- Women's Diagnostic Center - Munster
-
Valparaiso、Indiana、アメリカ、46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Boone、Iowa、アメリカ、50036
- McFarland Clinic - Boone
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Fort Dodge、Iowa、アメリカ、50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson、Iowa、アメリカ、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、アメリカ、50158
- McFarland Clinic - Marshalltown
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of the Lake Physician Group
-
Covington、Louisiana、アメリカ、70433
- Ochsner Hematology Oncology North Shore - Covington (West Region)
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek、Michigan、アメリカ、49017
- Bronson Battle Creek
-
Brighton、Michigan、アメリカ、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton、Michigan、アメリカ、48114
- Trinity Health Medical Center - Brighton
-
Canton、Michigan、アメリカ、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton、Michigan、アメリカ、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、アメリカ、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea、Michigan、アメリカ、48118
- Chelsea Hospital
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
Detroit、Michigan、アメリカ、48236
- Henry Ford Health Saint John Hospital
-
East China Township、Michigan、アメリカ、48054
- Henry Ford River District Hospital
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Flint、Michigan、アメリカ、48503
- Genesee Hematology Oncology PC
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Flint、Michigan、アメリカ、48503
- Cancer Hematology Centers - Flint
-
Grand Rapids、Michigan、アメリカ、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grosse Pointe Woods、Michigan、アメリカ、48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods、Michigan、アメリカ、48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49009
- Beacon Kalamazoo Cancer Center
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb、Michigan、アメリカ、48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Muskegon、Michigan、アメリカ、49444
- Trinity Health Muskegon Hospital
-
Niles、Michigan、アメリカ、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、アメリカ、49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi、Michigan、アメリカ、48377
- Henry Ford Medical Center-Columbus
-
Novi、Michigan、アメリカ、48374
- Henry Ford Health Providence Novi Hospital
-
Reed City、Michigan、アメリカ、49677
- Corewell Health Reed City Hospital
-
Saginaw、Michigan、アメリカ、48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、アメリカ、48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Southfield、Michigan、アメリカ、48075
- Henry Ford Health Providence Southfield Hospital
-
Sterling Heights、Michigan、アメリカ、48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City、Michigan、アメリカ、48764
- MyMichigan Medical Center Tawas
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Warren、Michigan、アメリカ、48093
- Macomb Hematology Oncology PC
-
Warren、Michigan、アメリカ、48093
- Henry Ford Health Warren Hospital
-
Warren、Michigan、アメリカ、48093
- Henry Ford Warren Hospital - GLCMS
-
West Bloomfield、Michigan、アメリカ、48322
- Henry Ford West Bloomfield Hospital
-
West Branch、Michigan、アメリカ、48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming、Michigan、アメリカ、49519
- University of Michigan Health - West
-
Ypsilanti、Michigan、アメリカ、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti、Michigan、アメリカ、48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Coon Rapids、Minnesota、アメリカ、55433
- Mercy Hospital
-
Deer River、Minnesota、アメリカ、56636
- Essentia Health - Deer River Clinic
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Edina、Minnesota、アメリカ、55435
- Fairview Southdale Hospital
-
Hibbing、Minnesota、アメリカ、55746
- Essentia Health Hibbing Clinic
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott-Northwestern Hospital
-
Robbinsdale、Minnesota、アメリカ、55422
- North Memorial Medical Health Center
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Sandstone、Minnesota、アメリカ、55072
- Essentia Health Sandstone
-
Virginia、Minnesota、アメリカ、55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Flemington、New Jersey、アメリカ、08822
- Hunterdon Medical Center
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Pinehurst、North Carolina、アメリカ、28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
-
Ohio
-
Belpre、Ohio、アメリカ、45714
- Strecker Cancer Center-Belpre
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Chillicothe、Ohio、アメリカ、45601
- Adena Regional Medical Center
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、アメリカ、43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus、Ohio、アメリカ、43228
- Doctors Hospital
-
Columbus、Ohio、アメリカ、43213
- Mount Carmel East Hospital
-
Columbus、Ohio、アメリカ、43215
- Grant Medical Center
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Dayton、Ohio、アメリカ、45415
- Miami Valley Hospital North
-
Dayton、Ohio、アメリカ、45415
- Dayton Physician LLC - Englewood
-
Dayton、Ohio、アメリカ、45409
- Premier Blood and Cancer Center
-
Delaware、Ohio、アメリカ、43015
- Delaware Health Center-Grady Cancer Center
-
Delaware、Ohio、アメリカ、43015
- Grady Memorial Hospital
-
Dublin、Ohio、アメリカ、43016
- Columbus Oncology and Hematology Associates
-
Franklin、Ohio、アメリカ、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin、Ohio、アメリカ、45005
- Dayton Physicians LLC-Atrium
-
Greenville、Ohio、アメリカ、45331
- Miami Valley Cancer Care and Infusion
-
Grove City、Ohio、アメリカ、43123
- Mount Carmel Grove City Hospital
-
Kettering、Ohio、アメリカ、45429
- Kettering Medical Center
-
Lancaster、Ohio、アメリカ、43130
- Fairfield Medical Center
-
Mansfield、Ohio、アメリカ、44903
- OhioHealth Mansfield Hospital
-
Marion、Ohio、アメリカ、43302
- OhioHealth Marion General Hospital
-
Marysville、Ohio、アメリカ、43040
- Memorial Hospital
-
Mount Vernon、Ohio、アメリカ、43050
- Knox Community Hospital
-
Newark、Ohio、アメリカ、43055
- Licking Memorial Hospital
-
Portsmouth、Ohio、アメリカ、45662
- Southern Ohio Medical Center
-
Springfield、Ohio、アメリカ、45504
- Springfield Regional Cancer Center
-
Springfield、Ohio、アメリカ、45504
- Springfield Regional Medical Center
-
Toledo、Ohio、アメリカ、43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy、Ohio、アメリカ、45373
- Upper Valley Medical Center
-
Westerville、Ohio、アメリカ、43081
- Saint Ann's Hospital
-
Zanesville、Ohio、アメリカ、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton、Oklahoma、アメリカ、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Clackamas、Oregon、アメリカ、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、アメリカ、97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg、Oregon、アメリカ、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City、Oregon、アメリカ、97045
- Providence Willamette Falls Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania/Abramson Cancer Center
-
West Reading、Pennsylvania、アメリカ、19611
- Reading Hospital
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Carolina
-
Boiling Springs、South Carolina、アメリカ、29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Easley、South Carolina、アメリカ、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、アメリカ、29650
- Prisma Health Cancer Institute - Greer
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- The Don and Sybil Harrington Cancer Center
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、アメリカ、75237
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth、Texas、アメリカ、76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Richardson、Texas、アメリカ、75080
- UT Southwestern Clinical Center at Richardson/Plano
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury、Vermont、アメリカ、05819
- Dartmouth Cancer Center - North
-
-
Washington
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Bridgeport、West Virginia、アメリカ、26330
- United Hospital Center
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton、Wisconsin、アメリカ、54911
- ThedaCare Regional Cancer Center
-
Ashland、Wisconsin、アメリカ、54806
- Duluth Clinic Ashland
-
Burlington、Wisconsin、アメリカ、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy、Wisconsin、アメリカ、53110
- Aurora Saint Luke's South Shore
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown、Wisconsin、アメリカ、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、アメリカ、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、アメリカ、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、アメリカ、53142
- Aurora Cancer Care-Kenosha South
-
Marinette、Wisconsin、アメリカ、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh、Wisconsin、アメリカ、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、アメリカ、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、アメリカ、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、アメリカ、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa、Wisconsin、アメリカ、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
-
-
-
-
Bayamón、プエルトリコ、00961
- Puerto Rico Hematology Oncology Group
-
San Juan、プエルトリコ、00927
- Centro Comprensivo de Cancer de UPR
-
San Juan、プエルトリコ、00936
- San Juan City Hospital
-
San Juan、プエルトリコ、00927
- PROncology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum. The date of diagnosis will be determined according to the pathologic date of diagnosis
-
Participants must have measurable disease according to RECIST1.1 criteria. Computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have documented unresectable and/or metastatic disease on CT or MRI imaging. All disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have BRAF^V600E mutated colorectal cancer as tested in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory
-
Participants must have proficient mismatch repair (pMMR) or microsatellite stable (MSS) status as tested in a CLIA-certified laboratory and documented by the treating clinician. Proficient mismatch repair status can be determined by intact expression by immunohistochemistry of all 4 mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). Microsatellite instability can be determined by polymerase chain reaction (PCR)
-
Participants with brain metastases must have completed surgery or radiation therapy >= 28 days prior to registration. These participants must have a CT or MRI of the brain showing no new or enlarging lesions within 42 days prior to registration. These participants must also be neurologically asymptomatic and without corticosteroid treatment for at least 7 days prior to registration. Metastatic brain parenchymal disease must have been treated and participant must be off steroids for 7 days prior to registration. The presence of leptomeningeal disease (LMD) is not considered stable disease, and participants with LMD are not eligible for this study
-
Participants with known evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration
-
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration
-
Participants must have had one or two prior regimens of systemic chemotherapy for metastatic or locally advanced, unresectable disease. (A maintenance regimen of 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted as a separate line of treatment. The re-introduction of an initially successful induction regimen will not be counted as one additional line of treatment). Prior treatment for metastatic disease is not required for patients who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy
-
Participants must be of age >= 18 years at the time of informed consent
-
Participants must have a Zubrod performance status of 0 or 1
-
Participants must have a complete medical history and physical exam within 28 days prior to registration
-
Absolute neutrophil count >= 1.0 x 10^3/uL (within 28 days prior to registration)
-
Hemoglobin >= 9 g/dL (within 28 days prior to registration)
-
Platelets >= 75 x 10^3/uL (within 28 days prior to registration)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to registration)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to registration)
-
If liver metastases are present, then it is acceptable for AST level =< 5.0 x ULN, and/or an ALT level =< 5.0 x ULN (within 28 days prior to registration)
-
Participants must have serum creatinine =< the IULN OR measured OR calculated creatinine clearance >= 50 mL/min using the Cockroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration
-
Participants must be able to swallow and retain pills
-
Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better
-
Participants with a known significant risk of corrected QT interval (QTc) prolongation must have an electrocardiogram (ECG) performed within 28 days prior to prior to registration
- Note: Per package insert for encorafenib, participants already at risk for development of QTc prolongation include those who "already have or who are at significant risk of developing QTc prolongation, including participants with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation."
-
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- Note: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Exclusion Criteria:
-
Participants must not have a known positive serology for human immunodeficiency virus (HIV). Encorafenib is contraindicated with concomitant use of non-nucleoside analog reverse transcriptase inhibitors like efavirenz and etravirine. In addition, it is recommended in the investigator brochure of encorafenib to avoid using encorafenib with protease inhibitors. Therefore, because all participants on this study would receive encorafenib for either randomized arm of treatment, participants with HIV who receive these components of highly active antiretroviral therapy (HAART) would be at high risk for complications of drug-drug interaction
-
Participants must not have had prior treatment with a BRAF inhibitor (including, but not limited to, encorafenib, dabrafenib, or vemurafenib), MEK inhibitor (including, but not limited to, trametinib, selumetinib, or binimetinib), or ERK inhibitor (of note, regorafenib is not considered a BRAF inhibitor for the context of eligibility criteria)
-
Participants must not have had prior treatment with anti-EGFR therapies
-
Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted, as long as there has been a washout period for corticosteroids of >= 7 days prior to registration
-
Participants must not have received a live vaccine within 30 days prior to study registration. Seasonal flu and COVID vaccines that do not contain a live virus are permitted
-
Participants must not be receiving any other investigational agents
-
Participants must not have impaired gastrointestinal function or disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
-
Participants must not have a history of inflammatory bowel disease, (including ulcerative colitis and Crohn's disease), symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); central nervous system (CNS) or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and myasthenia gravis, multiple sclerosis).
- Note: Participants with Graves' disease will be allowed
-
Participants must not have a history of pneumonitis that has required oral or intravenous (IV) steroids within the last 12 months
-
Participants must not have a history of a grade 3 or 4 allergic reaction attributed to humanized or human monoclonal antibody therapy
-
Participants must not have a history of a prior allogeneic tissue or solid organ transplant
-
Participants must not have a history of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) within 6 months prior to study registration
-
Participants must not have uncontrolled blood pressure and hypertension within 28 days prior to registration.
- Uncontrolled blood pressure and hypertension is defined as systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg within 28 days prior to registration. Participants are permitted to be receiving multiple anti-hypertensive medications (unless otherwise indicated in the study). All blood pressure measurements within the 28 days prior to registration must be SBP < 160 and DBP =< 100. An exception can be made by a healthcare provider for a participant with a single blood pressure elevation who upon rechecking has a normal blood pressure
-
Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen or requires concurrent therapy
-
Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion and vasectomy with testing showing no sperm in the semen
-
Participants must not be planning treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any type
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (encorafenib, cetuximab, nivolumab)
Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
|
|
アクティブコンパレータ:Arm II (encorafenib, cetuximab)
Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
Conducted in all eligible participants according to the intent-to-treat principle using the stratified log rank test when a total of 66 PFS events have been observed. Estimated using the Kaplan-Meier method and compared using the stratified log rank test. |
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR)
時間枠:Up to 3 years
|
Evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (confirmed and unconfirmed, complete and partial response) and compared across treatment arms via Fisher's exact test. |
Up to 3 years
|
|
Overall survival (OS)
時間枠:From date of registration to date of death due to any cause, assessed up to 3 years
|
Estimated using the Kaplan-Meier method and compared using the stratified log rank test. The distribution of OS will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
From date of registration to date of death due to any cause, assessed up to 3 years
|
|
Duration of response (DoR)
時間枠:From date of first documentation of confirmed response (complete response or partial response) to date of first documentation of progression or symptomatic deterioration or death due to any cause among participants who achieve a response, up to 3 years
|
Estimated using the Kaplan-Meier method and compared using the stratified log rank test. The distribution of DoR will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test. |
From date of first documentation of confirmed response (complete response or partial response) to date of first documentation of progression or symptomatic deterioration or death due to any cause among participants who achieve a response, up to 3 years
|
|
Immune related progression-free survival (irRC-PFS) in Arm I
時間枠:From date of registration to date of initial documentation of irRC-progression that has subsequently been confirmed or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
The distribution of irRC-PFS in Arm 1 (nivolumab + encorafenib + cetuximab) will be estimated using the method of Kaplan-Meier. |
From date of registration to date of initial documentation of irRC-progression that has subsequently been confirmed or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
|
Incidence of adverse events
時間枠:Up to 3 years
|
At least 25 eligible participants in each arm are sufficient to estimate the probability of a particular toxicity within ±20% (95% confidence interval), and any toxicity occurring with at least 10% probability is likely (93% chance) to be seen at least once. At least 50 eligible participants are sufficient to estimate the probability of a particular toxicity within ±14% (95% confidence interval), and any toxicity occurring with at least 5% probability is likely (92% chance) to be seen at least once. |
Up to 3 years
|
協力者と研究者
捜査官
- 主任研究者:Van K Morris、SWOG Cancer Research Network
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2022-02494
- U10CA180888 (米国 NIH グラント/契約)
- NCI-2022-02494 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- S2107 (その他の識別子:CTEP)
- S2107 (その他の識別子:SWOG)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。